- Bulk-forming agents
- Chloride channel activators
- Osmotic products
Chronic Idiopathic Constipation (CIC) Treatment Market size was estimated at USD 8.2 billion in 2022 and is poised to grow at a CAGR of 7.2% from 2023-2029. Chronic idiopathic constipation is a functional gastrointestinal disorder that leads to difficulty in defecating. It is a more chronic or severe condition and the symptoms of the disease include bloating, abdominal discomfort, hard stool, incomplete evacuation, gastric pain, and strain during the bowel movement. It is an idiopathic condition due to the causes of the disease are unclear, however, it may be due to psychological, neurological, and psychosomatic conditions. Chronic idiopathic constipation is majorly caused in adults or geriatric people. Diagnosis of CIC is difficult due to the lack of physiological causes and physicians look for symptoms like weight, blood in stool, and low blood count among others. The chronic idiopathic constipation Treatment market is growing at a significant CAGR owing to recent product approvals and competitor's focus on the development of newer drugs for CIC treatment. Moreover, an increase in the prevalence of chronic idiopathic constipation cases is also expected to propel the market revenue over the forecast period. Acquisitions and mergers, product approvals, and product launches are the key strategies adopted by the companies to increase their revenue share in the market. For instance, In January 2017, the FDA approved Tulane manufactured by Synergy Pharmaceuticals used in the treatment of chronic idiopathic constipation.
Fastest Growing Market
Increase in the prevalence of chronic idiopathic constipation due to change in lifestyle and food habits, rise in awareness about the CIC treatment, increase in the demand for CIC drugs, and availability of the over-the-counter CIC drugs in the market are driving the chronic idiopathic constipation treatment market. Moreover, various pipeline drugs for the CIC treatment and frequent product approvals from various drug regulatory bodies are propelling the chronic idiopathic constipation treatment market. However, lack of physiological symptoms for the disease and less number of drugs available for CIC treatment are the factors anticipated to hinder the growth of Chronic Idiopathic Constipation Treatment Market.
The chronic idiopathic constipation (CIC) treatment market is projected to expand at a CAGR of 7.2% during the forecast period
GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Allergan Plc. (Ireland), Ironwood Pharmaceuticals, Inc. (U.S.), Astellas Pharma, Inc. (Japan)
North America is the fastest-growing region for the chronic idiopathic constipation (CIC) treatment market